A detailed history of Rhumbline Advisers transactions in Eli Lilly & CO stock. As of the latest transaction made, Rhumbline Advisers holds 1,514,658 shares of LLY stock, worth $1.13 Billion. This represents 1.23% of its overall portfolio holdings.

Number of Shares
1,514,658
Previous 1,579,402 4.1%
Holding current value
$1.13 Billion
Previous $1.43 Billion 6.16%
% of portfolio
1.23%
Previous 1.36%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$772.14 - $960.02 $50 Million - $62.2 Million
-64,744 Reduced 4.1%
1,514,658 $1.34 Billion
Q2 2024

Aug 01, 2024

BUY
$724.87 - $909.04 $28.1 Million - $35.2 Million
38,762 Added 2.52%
1,579,402 $1.43 Billion
Q1 2024

May 09, 2024

SELL
$592.2 - $792.28 $15,989 - $21,391
-27 Reduced -0.0%
1,540,640 $1.2 Billion
Q4 2023

Feb 08, 2024

SELL
$525.19 - $619.13 $7.43 Million - $8.76 Million
-14,145 Reduced 0.91%
1,540,667 $898 Million
Q3 2023

Nov 09, 2023

BUY
$434.7 - $599.3 $4.18 Million - $5.76 Million
9,618 Added 0.62%
1,554,812 $835 Million
Q2 2023

Aug 08, 2023

BUY
$350.74 - $468.98 $5.86 Million - $7.84 Million
16,711 Added 1.09%
1,545,194 $725 Million
Q1 2023

May 11, 2023

BUY
$310.63 - $364.82 $18.2 Million - $21.3 Million
58,471 Added 3.98%
1,528,483 $525 Million
Q4 2022

Feb 14, 2023

BUY
$321.55 - $374.67 $18.9 Million - $22 Million
58,785 Added 4.17%
1,470,012 $538 Million
Q3 2022

Nov 10, 2022

BUY
$296.48 - $337.87 $8.45 Million - $9.63 Million
28,492 Added 2.06%
1,411,227 $456 Million
Q2 2022

Aug 11, 2022

BUY
$278.73 - $327.27 $8.7 Million - $10.2 Million
31,229 Added 2.31%
1,382,735 $448 Million
Q1 2022

May 12, 2022

BUY
$234.69 - $291.66 $4.73 Million - $5.87 Million
20,139 Added 1.51%
1,351,506 $387 Million
Q4 2021

Feb 10, 2022

BUY
$224.85 - $279.04 $5.01 Million - $6.21 Million
22,262 Added 1.7%
1,331,367 $368 Million
Q3 2021

Nov 12, 2021

SELL
$221.6 - $272.71 $8.3 Million - $10.2 Million
-37,477 Reduced 2.78%
1,309,105 $302 Million
Q2 2021

Aug 05, 2021

SELL
$180.55 - $233.54 $12.4 Million - $16.1 Million
-68,918 Reduced 4.87%
1,346,582 $309 Million
Q1 2021

May 06, 2021

SELL
$164.32 - $212.72 $15.8 Million - $20.4 Million
-95,984 Reduced 6.35%
1,415,500 $264 Million
Q4 2020

Feb 10, 2021

SELL
$130.46 - $172.63 $3.25 Million - $4.3 Million
-24,882 Reduced 1.62%
1,511,484 $255 Million
Q3 2020

Nov 12, 2020

SELL
$146.22 - $169.13 $2.16 Million - $2.5 Million
-14,780 Reduced 0.95%
1,536,366 $227 Million
Q2 2020

Aug 13, 2020

BUY
$136.42 - $164.18 $13.5 Million - $16.3 Million
99,105 Added 6.83%
1,551,146 $255 Million
Q1 2020

May 06, 2020

SELL
$119.05 - $147.35 $1.79 Million - $2.21 Million
-15,011 Reduced 1.02%
1,452,041 $201 Million
Q4 2019

Feb 05, 2020

SELL
$106.92 - $132.43 $1.89 Million - $2.34 Million
-17,652 Reduced 1.19%
1,467,052 $193 Million
Q3 2019

Oct 23, 2019

BUY
$106.79 - $116.16 $3.08 Million - $3.35 Million
28,867 Added 1.98%
1,484,704 $166 Million
Q2 2019

Aug 14, 2019

SELL
$110.79 - $129.32 $7.61 Million - $8.88 Million
-68,660 Reduced 4.5%
1,455,837 $161 Million
Q1 2019

May 01, 2019

SELL
$111.31 - $131.02 $1.57 Million - $1.85 Million
-14,146 Reduced 0.92%
1,524,497 $198 Million
Q4 2018

Jan 31, 2019

BUY
$105.9 - $118.64 $1.37 Million - $1.54 Million
12,962 Added 0.85%
1,538,643 $178 Million
Q3 2018

Nov 07, 2018

SELL
$85.86 - $107.31 $2.76 Million - $3.45 Million
-32,180 Reduced 2.07%
1,525,681 $164 Million
Q2 2018

Aug 06, 2018

BUY
$75.7 - $86.88 $1.41 Million - $1.61 Million
18,581 Added 1.21%
1,557,861 $133 Million
Q1 2018

May 02, 2018

SELL
$74.21 - $87.6 $2.78 Million - $3.29 Million
-37,509 Reduced 2.38%
1,539,280 $119 Million
Q4 2017

Feb 09, 2018

BUY
$81.94 - $87.89 $2.9 Million - $3.11 Million
35,349 Added 2.29%
1,576,789 $133 Million
Q3 2017

Nov 06, 2017

BUY
$77.07 - $85.54 $119 Million - $132 Million
1,541,440
1,541,440 $132 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $709B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.